Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Stopped Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care in the recurrent and metastatic cervical cancer setting.

Conditions

• HPV-Related Cervical Carcinoma
• HPV-Related Malignancy
• Cervical Cancer

Interventions

• BIOLOGICAL: VB10.16
• DRUG: Atezolizumab Injection [Tecentriq]
• DRUG: Placebo

Sponsor

Nykode Therapeutics ASA

Collaborators

• [object Object]
• [object Object]